The Dopamine D1 Receptors

  • Hyman B. Niznik
  • Roger K. Sunahara
  • Hubert H. M. Van Tol
  • Philip Seeman
  • David M. Weiner
  • Tom M. Stormann
  • Mark R. Brann
  • Brian F. O’Dowd
Part of the Applications of Molecular Genetics to Pharmacology book series


Many psychomotor signs and symptoms are influenced by the activity of dopaminergic neurons and by drugs that selectively interact with neuronal dopamine receptors. These include rigidity in Parkinson’s disease, hallucinations in schizophrenia and Alzheimer’s disease, dyskinesia in Huntington’s chorea, and spontaneous oral dyskinesia in the elderly (Seeman, 1987; Seeman et al., 1987; Seeman and Niznik, 1990). These receptors may also play a significant role in drug addiction and alcoholism (Blum et al., 1990). On the basis of pharmacological, biochemical, and physiological criteria, receptors for dopamine have been classified into two types, termed D1 and D2 (Kebabian and Calne, 1979; Seeman, 1980; Niznik and Jarvie, 1989). These are members of a large gene family of hormone/neurotransmitter receptors that exert their biological actions via signal transduction pathways that involve guanine nucleotide-binding proteins. While D2 dopamine receptors inhibit the activation of adenylyl cyclase and appear to couple to numerous other effector systems, D1 dopamine receptors, found in the brain, retina, and parathyroid gland, stimulate adenylyl cyclase and subsequently activate cAMP-dependent protein kinases (Niznik, 1987; Seeman and Niznik, 1988; Hess and Creese, 1987; Hemmings et al., 1987).


Dopamine Receptor Intronless Gene Degenerate Polymerase Chain Reaction Oligonucleotide Primer Bovine Parathyroid Gland Spontaneous Oral Dyskinesia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andersen PH, Gingrich J A, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron MG (1990): Dopamine receptor subtypes: Beyond the D1/D2 classification. Trends Pharmacol Sci 11: 231–236CrossRefGoogle Scholar
  2. Ashkenazi A, Ramachandran J, Capon DJ (1989): ACH analogue stimulate DNA synthesis in brain cells via specific muscarinic receptor subtypes. Nature 340: 146–150CrossRefGoogle Scholar
  3. Basset AS, McGilvray BC, Jones BD, Pantzar JT (1988): Partial trisomy of chromosome 5 cosegregating with schizophrenia. Lancet i: 799–801Google Scholar
  4. Benovic JL, Deblasi A, Stone WC, Caron MG, Lefkowitz RJ (1989): ß-Adrenergic receptor kinase: Primary structure delineates a multigene family. Science 246: 235–246CrossRefGoogle Scholar
  5. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswarran P, Nogami H, Briggs AH, Cohn JB (1990): Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 263: 2055–2060CrossRefGoogle Scholar
  6. Brown EM, Chen CJ, Niznik HB, Fogel EL, Hawkins D (1989): Control of parathyroid function by dopamine: Characterization of D1 receptors and their interaction with other secretagogues in bovine parathyroid cells. In: Peripheral Dopamine Pathophysiology, Amenta F, ed. Boca Raton, Florida: CRC Press, pp 99–116Google Scholar
  7. Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O (1988): Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783–787CrossRefGoogle Scholar
  8. Clark D, White FJ (1987): D1 dopamine receptor — the search for a function. Synapse 1: 347–388CrossRefGoogle Scholar
  9. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeberg PH (1989): The dopamine D2 receptor: Two molecular forms generated by alternative splicing. EMBO J 8 (13): 4025–4034Google Scholar
  10. Dearry AG, Gingrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990): Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72–76CrossRefGoogle Scholar
  11. Detera-Wadleigh DDD, Goldin LR, Sherrington R, Encio I, de Miiguel C, Berrettini W, Gurling H, Gershon ES (1989): Exclusion of linkage to 5qll-13 in families with schizophrenia and other psychiatric disorders. Nature 340: 391–393CrossRefGoogle Scholar
  12. Felder RA, Felder CC, Eisner GM, Jose PA (1989): The dopamine receptor in adult and maturing kidney. Am J Physiol 257: F315–F327Google Scholar
  13. Gilliam TC, Freimer NB, Kaufman CA, Powchik PP, Basset AS, Bengtsson U, Wasmuth J J (1989): Deletion mapping of DNA markers to a region of chromosome 5 that co-segregates with schizophrenia. Genomics 5: 940–944CrossRefGoogle Scholar
  14. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli, O (1989): Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86: 9762–9766CrossRefGoogle Scholar
  15. Grandy DK, Zhou QY, Allen L, Litt R, Magenis E, Civelli O, Litt M (1990): A human D1 dopamine receptor gene is located on chromosome 5 at q35.1 and identifies an Eco R1 RFLP. Amer J Hum Genet 47: 828–834Google Scholar
  16. Gutkind C, Novotny E, Brann MR, Robbins K (1991): Muscarinic receptors as agonist dependent oncogenes. Proc Natl Acad Sci USA 88: 1459–1463CrossRefGoogle Scholar
  17. Hartmann E, Rapoport TA, Lodish HF (1989): Predicting the orientation of eukaryotic membrane spanning proteins. Proc Natl Acad Sci USA 86: 5786–5790CrossRefGoogle Scholar
  18. Hemmings HC, Walaas SI, Oiumet CC, Greengard P (1987): Dopaminergic regulation of protein phosphorylation in the striatum: DARP-32. Trends Neurosci 10: 77–82CrossRefGoogle Scholar
  19. Hess EJ, Creese I (1987): Biochemical characterization of dopamine receptors. In Receptor Biochemistry and Methodology: Dopamine Receptors, Creese I, Fraser CM, New York: Liss, Vol 8, pp 57–71Google Scholar
  20. Jarvie KR, Booth G, Brown EM, Niznik HB (1989): Glycoprotein Nature of dopamine D1 receptors. Mol Pharmacol 34: 566–574Google Scholar
  21. Kebabian JW, Calne DB (1979): Multiple receptors for dopamine. Nature 277: 93–96CrossRefGoogle Scholar
  22. Kennedy JL, Giuffra LA, Moises HW, Cavalli-Sforza LL, Pakstis AJ, Kidd JR, Castiglione CM, Sjogren B, Wetterberg L, Kidd KK (1988): Evidence against linkage of schizophrenia to markers on chromosome 5 in a northern Swedish kindred. Nature 336: 167–170CrossRefGoogle Scholar
  23. Kobilka BK, Frielle T, Dohlman HG, Bolanowski MA, Dixon RAF, Keller P, Caron MG, Lefkowitz RJ (1987): Delineation of the intronless Nature of the genes for the human and hamster ß2-adrenergic receptor and their putative promoter regions. J Biol Chem 262 (15): 7321–7327Google Scholar
  24. Lankford KL, Demello FG, and Klein WL (1988): D1 type dopamine receptors inhibit growth cone motility in cultured retinal neurons: Evidence that neurotransmitters act as morphogenic regulators in the developing nervous system. Proc Natl Acad Sci USA 85: 2839–2843CrossRefGoogle Scholar
  25. Mahan LC, Burch RM, Monsma FJ, Sibley DR (1990): Expression of striatal D1 dopamine receptors coupled to inositolphosphate production and calcium mobilization in Xenopus oocytes. Proc Natl Acad Sci USA 87: 2196–2200CrossRefGoogle Scholar
  26. Mengod G, Vilaro MT, Niznik HB, Sunahara RK, Seeman P, O’Dowd BF, Palacios JM (1991): Visualization of a dopamine D1 receptor mRNA in human and rat brain. Mol Brain Res 10: 185–191CrossRefGoogle Scholar
  27. Niznik HB (1987): Dopamine receptors; molecular structure and function. Mol Cell Endocrinol 54: 1–22CrossRefGoogle Scholar
  28. Niznik HB, Fogel EL, Chen CJ, Congo D, Brown EM, Seeman P (1988a): Dopamine D1 receptors of the calf parathyroid gland; Identification and characterization. Mol Pharmacol 34: 29–36Google Scholar
  29. Niznik HB, Jarvie KR, Bzowej NH, Seeman P, Garlick RK, Miller JJ, Baindur N, Neumeyer JL (1988b): Photoaffinity labeling of dopamine D1 receptors. Biochemistry 27: 7594–7599CrossRefGoogle Scholar
  30. Niznik HB, Jarvie KR (1989): Dopamine receptors. In: Receptor Pharmacology and Function, Williams M, Glennon RA, Timmermans PBMWM eds. New York: Dekker, pp 717–768Google Scholar
  31. Niznik HB, Jarvie KR, Brown EM (1989): Dopamine D1 receptors of the calf parathyroid gland: Identification of a ligand binding subunit with lower apparent molecular weight but similar primary structure to neuronal D1 receptors. Biochemistry 28: 6925–6930CrossRefGoogle Scholar
  32. O’Dowd BF, Hnatowich M, Regan JW, Leader WM, Caron MG, Lefkowitz RJ (1988): Site directed mutagenesis of the cytoplasmic domains of the human ß2-adrenergic receptor. J Biol Chem 263: 15985–15992Google Scholar
  33. O’Dowd BF, Lefkowitz RJ, Caron MG (1989a): Structure of the adrenergic and related receptors. Annu Rev Neurosci 12: 67–83CrossRefGoogle Scholar
  34. O’Dowd BF, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M (1989b): Palmitoylation of the human ß-adrenergic receptor: Mutation of cys341 in the carboxy tail leads to an uncoupled nonpalmitylated form of the receptor. J Biol Chem 264 (13): 7564–7569Google Scholar
  35. O’Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, Seeman P, Niznik HB (1990): Cloning of two additional catecholamine receptors from rat brain. FEBS Lett 262: 8–12CrossRefGoogle Scholar
  36. O’Dowd BF, Hnatowich M, Lefkowitz RJ (1991a): Adrenergic and related G protein coupled receptors: Structure and function. Encycl Hum Biol 1: 81–92Google Scholar
  37. O’Dowd BF, Nguyen T, Jin H, Grupp L, Seeman P (1991b): Two human pseudogenes homologous to the D5 dopamine receptors. Abstr Neurosci Soc 17: 598Google Scholar
  38. Ovchinnikov YA, Abdulaev NG, Bogachuk AS (1988): Two adjacent cysteine residues in the c-terminal cytoplasmic fragment of bovine rhodopsin are palmitylated. FEBS Lett 230: 1–5CrossRefGoogle Scholar
  39. Seeman P (1980): Dopamine receptors. Pharmacol Rev 32: 229–313Google Scholar
  40. Seeman P (1987): Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152CrossRefGoogle Scholar
  41. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987): Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s and Huntington’s diseases. Neuropsychopharmacology 1: 5–15CrossRefGoogle Scholar
  42. Seeman P, Niznik HB (1988): Dopamine D1 receptor pharmacology. ISI Atlas Sci: Pharmacol 2: 161–170Google Scholar
  43. Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C (1989): Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86: 10156–10160CrossRefGoogle Scholar
  44. Seeman P, Niznik HB (1990): Dopamine receptors and transporters in Parkinson’s disease and schizophrenia. FASEB/4: 2737–2744Google Scholar
  45. Sherrington R, Brynjolfsson J, Petursson H, Potter M, Dudleston K, Barraclough B, Wasmuth J, Dobbs M, Gurling H (1988): Localization of a susceptibility locus for schizophrenia on chromosome 5. Nature 336: 164–167CrossRefGoogle Scholar
  46. Sokoloff P, Giros B, Martes MP, Bouthenet ML, Schwartz JC (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151CrossRefGoogle Scholar
  47. Stormann TM, Gdula P, Weiner DM, Brann MR (1990): Molecular cloning and expression of a dopamine D2 receptor from human retina. Mol Pharmacol 37: 1–6Google Scholar
  48. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RAF (1987): Identification of residues required for ligand binding to the ß-adrenergic receptor. Proc Natl Acad Sci USA 84: 4384–4388CrossRefGoogle Scholar
  49. Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RAF (1989a): Identification of two serine residues involved in agonist activation of the ß-adrenergic receptor. J Biol Chem 264: 13572–13578Google Scholar
  50. Strader CD, Sigal IS, Dixon RAF (1989b): Structural basis of ß-adrenergic receptor function. FASEB J 3: 1825–1832Google Scholar
  51. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelerntner JL, Rozmahel R, Yang Y, Israel Y, Seeman P, O’Dowd BF (1990): Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 347: 80–83CrossRefGoogle Scholar
  52. Sunahara RK, Guan H-C, O’Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Toi HHM, Niznik HB (1991): Cloning a human dopamine receptor gene (D5) with higher affinity for dopamine than Dl. Nature 350: 614–619CrossRefGoogle Scholar
  53. Van Toi HHM, Bunzow JR, Guan HG, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350: 610 - 614CrossRefGoogle Scholar
  54. Waddington JL (1989): Functional interactions between Dl and D2 dopamine receptor systems. J Psychopharmacol 3: 54–63CrossRefGoogle Scholar
  55. Waddington JL, O’Boyle KM (1989): Drug acting on dopamine receptors: A conceptual réévaluation five years after the first selective Dl antagonist. Pharmacol Ther 43: 1–52Google Scholar
  56. Weiner DM, Brann MR (1989): The distribution of dopamine D2 receptor mRNA in rat brain. FEBS Lett 253: 207–213CrossRefGoogle Scholar
  57. Weiner DM, Levey AI, Sunahara RK, Niznik HB, O’Dowd BF, Brann MR (1991): Dopamine Dl and D2 receptor mRNA expression in rat brain. Proc Natl Acad Sci USA 88: 1859–1863CrossRefGoogle Scholar
  58. Yang-Feng TL, Fhong XF, Cotecchia S, Frielle T, Caron MG, Lefkowitz RJ (1990): Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci USA 87: 1516–1520CrossRefGoogle Scholar
  59. Zhou QY, Grandy DK, Thambi L, Kushner JA, Van Toi HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O (1990): Cloning and the expression of human and rat Dl dopamine receptors. Nature 347: 76–80CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Hyman B. Niznik
  • Roger K. Sunahara
  • Hubert H. M. Van Tol
  • Philip Seeman
  • David M. Weiner
  • Tom M. Stormann
  • Mark R. Brann
  • Brian F. O’Dowd

There are no affiliations available

Personalised recommendations